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Abstract The plasmin–antiplasmin system plays a key
role in blood coagulation and fibrinolysis. Plasmin and
a2-antiplasmin are primarily responsible for a controlled
and regulated dissolution of the fibrin polymers into solu-
ble fragments. However, besides plasmin(ogen) and
a2-antiplasmin the system contains a series of specific
activators and inhibitors. The main physiological activators
of plasminogen are tissue-type plasminogen activator,
which is mainly involved in the dissolution of the fibrin
polymers by plasmin, and urokinase-type plasminogen
activator, which is primarily responsible for the generation
of plasmin activity in the intercellular space. Both activa-
tors are multidomain serine proteases. Besides the main
physiological inhibitor a2-antiplasmin, the plasmin–anti-
plasmin system is also regulated by the general protease
inhibitor a2-macroglobulin, a member of the protease
inhibitor I39 family. The activity of the plasminogen
activators is primarily regulated by the plasminogen
activator inhibitors 1 and 2, members of the serine protease
inhibitor superfamily.
Keywords Plasmin(ogen)  a2-Antiplasmin  Serine
protease inhibitors (serpins)  Plasminogen activators 
Plasminogen activator inhibitors  a2-Macroglobulin 
Multidomain serine proteases
Abbreviations
A2PI a2-Antiplasmin, a2-Plasmin inhibitor
CHO Carbohydrate
EGF-like Epidermal growth factor-like
FN1 Fibronectin type I
K Kringle
LBS Lysine binding site
LMW Low molecular weight
a2M a2-Macroglobulin
NTP N-terminal peptide of Pgn
PAI-1, -2 Plasminogen activator inhibitor 1, 2
Pgn Plasminogen
Plm Plasmin
RCL Reactive centre loop
Serpin Serine protease inhibitor
tPA Tissue-type plasminogen activator
uPA Urokinase-type plasminogen activator
uPAR Urokinase-type plasminogen activator receptor
Introduction [1]
The plasmin–antiplasmin system holds a key position in
blood coagulation and fibrinolysis. A schematic represen-
tation of the fibrinolytic system with its main components
is given in Fig. 1 [2]. The plasmin–antiplasmin system
controls and regulates the dissolution of the fibrin polymers
into soluble fragments (for details see later sections). As
with every complex system, blood coagulation and fibri-
nolysis also have to be tightly controlled and regulated.
Plasminogen (Pgn) is activated by its two main physio-
logical activators, tissue-type plasminogen activator (tPA)
The recommended names in the UniProt Knowledgebase (SwissProt
and TrEMBL) were used. The protein structures are based on the
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visualized as well as rendered using the software PyMOL. If not
stated otherwise, the standard rainbow colour representation was
used.
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and urokinase-type plasminogen activator (uPA). Plasmin
(Plm) is inhibited by its main physiological inhibitor
a2-antiplasmin (A2PI) and the general protease inhibitor
a2-macroglobulin (a2M). The activities of tPA and uPA are
regulated by their two main physiological inhibitors, the
plasminogen activator inhibitors 1 and 2 (PAI-1 and PAI-2).
The structural data for the proteins involved in the
plasmin–antiplasmin system discussed in this review arti-
cle are compiled in Table 1.
Multidomain serine proteases
Many serine proteases in blood plasma are multidomain
proteins, especially those involved in blood coagulation
and fibrinolysis and those in the complement system.
Usually, serine proteases are present in plasma in their
inactive proenzyme or zymogen form. The catalytic
activity is normally generated by a specific activation
process involving limited proteolysis. The 3-D structure of
a serine protease domain is usually characterized by two
six-stranded antiparallel b-barrels surrounded by a-helical
and 310-helical segments. The active site cleft with the
catalytic triad His, Asp, and Ser is located at the interface
of two structurally similar subdomains (see sections:
Plasminogen, Tissue-type plasminogen activator, and
Urokinase-type plasminogen activator). Besides the serine
protease domain, multidomain serine proteases contain
specific domains such as kringles, fibronectin (FN), and
epidermal growth factor-like (EGF-like) domains, which
mediate efficient binding to the target structures thus
facilitating an efficient cleavage reaction of the serine
protease which is usually strictly limited to the intended
site. For instance, efficient binding of plasmin(ogen) to the
fibrin blood clot is mediated by the lysine binding sites
(LBS) located in the kringle domains of the molecule thus
facilitating an efficient cleavage of the fibrin polymer by
Plm into soluble fragments (for details see section Plas-
minogen). The most important structural data for the
multidomain serine proteases Pgn, tPA, and uPA are
summarized in Table 1.
Plasminogen [3–6]
Human Pgn (P00747, EC 3.4.21.7; concentration in plasma
100–200 mg l-1) is a single-chain, multidomain glyco-
protein (about 2% CHO) of about 90 kDa (791 amino
acids) and is a member of the peptidase S1 family present
in blood as zymogen. Pgn is synthesized mainly in the liver
as a protein 810 residues long [7], and mature Pgn, Glu-
Pgn, comprises 791 amino acids generated during the
secretion process by cleaving the 19-residue signal peptide
[8]. Glu-Pgn is the proenzyme form of the serine protease
Plm, the key component of the fibrinolytic system (Fig. 1).
The gene for Pgn (PLG, 52.5 kb) is located on chromo-
some 6q26-6q27 and is organized into 19 exons in the
range 75–387 bp [8–10]. In plasma, Pgn is partially bound
to histidine-rich glycoprotein (P04196) [11]. Histidine-rich
glycoprotein binds at sites of tissue injury and seems to
act as a high-affinity receptor to immobilize Pgn on cell
surfaces [12].
Pgn is composed of an N-terminal peptide (NTP) [13],
five triple-loop structures stabilized by three intrachain
disulfide bridges called kringles [14], and the trypsin-like
serine protease part carrying the catalytic triad His603,
Asp646, and Ser741 [15]. Human Pgn is partially N-gly-
cosylated at Asn289 and O-glycosylated at Ser249 and
Thr346 giving rise to Pgn variants I (Asn289, Thr346) and II
(only Thr346), which can be readily separated by affinity
chromatography [16–20]. In addition, Pgn is partially
phosphorylated at Ser578 [21] with a so far unassigned
function. The schematic organization of the primary
structure of human Pgn is shown in Fig. 2 [2]. Two
N-terminally different forms of Pgn have been identified,
Glu-Pgn and Lys-Pgn. Lys-Pgn is formed by cleavage of
the Lys77–Lys78 peptide bond in Glu-Pgn, releasing the
NTP [22].
Pgn is activated by the two main physiological plas-
minogen activators, tPA and uPA [23], to the active, two-
chain Plm molecule held together by two interchain
disulfide bridges (Cys548–Cys666, Cys558–Cys566) by
cleavage of the Arg561–Val562 peptide bond and the release
of the 77-residue NTP [24, 25]. Upon activation, Pgn
undergoes an unusual conformational change usually not
observed in proenzyme–enzyme pairs of the trypsin-type
family [25]. Native Glu-Pgn exhibits a compact spiral
shape, whereas Lys-Pgn and Plm have a more open,
elongated structure. In addition to tPA and uPA, two
bacteria-derived proteins, streptokinase A or C (A: P10520;
Fig. 1 Schematic representation of the main components of the
fibrinolytic system (adapted from reference [2]). sc-tPA, tc-tPA
single-chain, two-chain tPA; sc-uPA, tc-uPA single-chain, two-chain
uPA; PAIs plasminogen activator inhibitors
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C: P00779) and staphylokinase (P68802), can act as Pgn
activators. They form equimolar complexes with Pgn, and
this complex is able to activate Pgn [26, 27].
The heavy chain of Plm (483 amino acids) contains five
homologous kringle structures, K1 (Cys84–Cys162), K2
(Cys166–Cys243), K3 (Cys256–Cys333), K4 (Cys358–Cys435),
and K5 (Cys462–Cys541), with the disulfide bridges arran-
ged in the pattern Cys1–Cys6, Cys2–Cys4, Cys3–Cys5.
Kringles 2 and 3 are linked together in a clamp-like
fashion by an additional interkringle disulfide bridge
(Cys169–Cys297). With the exception of K3, each kringle
contains a functional LBS characterized by anionic and
cationic centres interspaced by a hydrophobic groove. In
the case of human Pgn K1, the anionic and cationic centres
contain two Asp and two Arg residues, respectively, and
the hydrophobic groove is lined out with aromatic residues
(one Trp, three Tyr, and one Phe) [28, 29]. The LBS
mediate binding to the substrate fibrin(ogen) [30] and to its
main physiological inhibitor A2PI [31–33] and to small
molecules of the x-aminocarboxylic acid type such as
Table 1 Structural data for the main proteins involved in the plasmin–antiplasmin system
Protein (abbreviation) UniProt entry Sizeb Plasma
concentration
(mg l-1)
Gene Domains
Daltons Amino
acids
Name Size
(kb)
Plasminogen (Pgn) P00747/EC 3.4.21.7 88,432 791 100–200 PLG 52.5 1 NTP of Pgn, 5 K,
serine protease
Tissue-type plasminogen
activator (tPA)
P00750/EC 3.4.21.68 59,042 527 0.005–0.01 PLAT 32.4 1 EGF-like, 2 K,
1 FN1,
serine protease
Urokinase-type plasminogen
activator (uPA)
P00749/EC 3.4.21.73 46,386 411 0.005–0.01 PLAU 6.4 1 EGF-like,
1 K, serine
protease
a2-Antiplasmin (A2PI) P08697 50,451 452 *70 SERPINF2 *16
a2-Macroglobulin (a2M) P01023 160,797 1,451 *1,200 A2M *48
Plasminogen activator
inhibitor 1 (PAI-1)
P05121 42,769 379 *0.024 (variable) SERPINE1 12.2
Plasminogen activator
inhibitor 2 (PAI-2)
P05120 46,596 415 \0.01 SERPINB2 16.4
Neuroserpin Q99574 44,704 394 not detectable SERPINI1 89.8
Glia-derived nexin P07093 41,865 379 SERPINE2 –
b Mass calculated from the amino acid sequence
Fig. 2 Schematic
representation of the primary
structure of human Pgn (from
reference [2]). The catalytic
triad (His603, Asp646, and
Ser741), the activation site
(Arg561–Val562), the Plm
cleavage site (Lys77–Lys78), the
phosphorylation site (Ser578),
the CHO attachment sites
(Asn289, Ser249, and Thr346), and
the 24 disulfide bridges as well
as the signal peptide are
indicated. NTP N-terminal
peptide; K1–K5 kringles 1–5
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6-aminohexanoic acid [34]. In addition, specific binding
via kringle domain(s) to bacteria [35, 36] and to mamma-
lian cell surfaces [37] has been described. K3 is the only
kringle with a functionally inactive LBS [38, 39], but
substitution of Lys311 to Asp in the anionic centre of the
LBS results in a weak but distinct affinity for x-amino-
carboxylic acids [40]. The affinity of the antifibrinolytic
drug 6-aminohexanoic acid for the various kringles
decreases in the order K1 [ K4 [ K5 [ K2 [[ K3
[41–43].
So far, no 3-D structure of complete human Pgn is
available. A 3-D structural model of human Pgn based on
known and overlapping 3-D structures of Pgn fragments
exhibits the spiral shape shown in Fig. 3 [44], which
resembles the known shape of Glu-Pgn visualized by
electron microscopy [45, 46]. However, 3-D structural data
for all kringle domains and of the catalytic chain are
available. As an example, the 3-D structures of the triple-
kringle domain K1 ? 2 ? 3 termed angiostatin (1KI0),
determined by X-ray diffraction, is shown in Fig. 4 [47].
The kringle structures are characterized by a central cluster
of four Cys residues composed of the two inner disulfide
bridges (Cys2–Cys4, Cys3–Cys5), which are almost per-
pendicular to each other (as an example, see K2). The
kringle domains have a rather low content of secondary
structure with some b-strands but usually a low helical
content. As an example, K1 is given in the surface repre-
sentation with negatively and positively charged residues
shown in red and in blue, respectively, and all other resi-
dues are shown in grey. The central Trp residue of the LBS
is marked in magenta (indicated by an arrow). The binding
of a ligand has little influence on the conformation but
stabilizes the structure. The 3-D structure of the catalytic
domain of human Pgn determined by X-ray diffraction
(1DDJ) exhibits the expected trypsin-like shape, and is
shown in Fig. 5 [25]. Each of the two structurally similar
subdomains is characterized by an antiparallel b-barrel and
the active site cleft is located at the interface of the two
subdomains.
The primary function of Plm is the cleavage of insoluble
fibrin polymers at specific sites resulting in soluble frag-
ments. A schematic representation of fibrinogen and the
pattern of cleavage by Plm is shown in Fig. 6 [48]. The
cleavage sites giving rise to the major fragments D and E of
fibrin are indicated by black arrows. The degradation of the
fibrin polymer by Plm is initiated by the cleavage of the
Lys583–Met584 peptide bond in the Aa chain, followed by
Fig. 3 Top and bottom 3-D
structural model of human Pgn
based on overlapping 3-D
structures of Pgn fragments
(form reference [44]). Each
kringle is shown in grey, the
central Trp residue in each LBS
is shown in magenta, the
protease domain is shown in
green, and the active site
residues are shown in red
Fig. 4 3-D structure of human Pgn kringles 1 ? 2 ? 3 (K1, K2, K3)
termed angiostatin determined by X-ray diffraction (1KI0, [47]). Each
kringle contains three disulfide bridges (yellow) arranged in the
pattern Cys1–Cys6, Cys2–Cys4, Cys3–Cys5 exemplified in kringle 2
(K2). Kringle 1 (K1) is shown as a surface representation with
negatively and positively charged residues shown in red and blue,
respectively, and all other residues are shown in grey. The central Trp
residue of the LBS is shown in magenta (arrow)
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the cleavage of the peptide bonds Lys206–Met207 and
Lys230–Ala231, also in the Aa chain, thus releasing a
C-terminal 40-kDa fragment and generating fragment X
(260 kDa). Cleavage of fragment X in all three chains
results in one fragment Y (160 kDa) and one fragment D
(100 kDa), and further cleavage of fragment Y produces a
second fragment D and fragment E (60 kDa) [48].
In addition, Plm acts as a proteolytic factor in many
other physiological processes such as mediation of cell
migration by degrading the extracellular matrix, wound
healing, tissue remodelling, angiogenesis, embryogenesis,
and pathogen and tumour cell invasion [23, 49–54]. The
rather broad specificity of Plm in vivo results in the
inactivation and degradation of matrix proteins such as
collagens, fibronectin (P02751), and laminins [55–57], and
components of the blood coagulation cascade such as
coagulation factor FVa, von Willebrand factor, and
thrombospondin [56, 58, 59]. In vitro, Plm has a similar
specificity to trypsin cleaving primarily peptide bonds after
basic residues. The main physiological inhibitor of Plm is
A2PI, a serpin, which is discussed in section a2-Antiplas-
min or a2-plasmin inhibitor.
Defects or mutations in the PLG gene are the cause of
thrombophilia (MIM 188050) [60], a form of recurrent
thrombosis, and type I plasminogen deficiency (MIM
173350). Ligneous conjunctivitis (MIM 217090) is usually
the most common and initial form of type I plasminogen
deficiency and is a rare form of chronic conjunctivitis
characterized by chronic tearing and redness of the con-
junctivae [61, 62].
Plasminogen activators
There are two main physiological activators of Pgn, tPA
and uPA, which are both multidomain serine proteases
previously mentioned (see Table 1). Although tPA and
uPA both catalyse the same reaction, namely the activation
of Pgn to Plm by cleavage of the Arg561–Val562 peptide
bond, and thus clearly have the same basic biological
function at the molecular level, tPA and uPA have different
biological roles. Whereas tPA is primarily responsible for
the dissolution of the fibrin polymers by Plm and thus helps
to maintain vascular haemostasis, uPA is predominantly
involved in the generation of pericellular Plm activity for
the degradation of the extracellular matrix and for other
intercellular processes where Plm activity is required.
Fig. 5 3-D structure of the catalytic domain of human Pgn
determined by X-ray diffraction (1DDJ, [25]). The active site residues
located at the interface of the two structurally similar subdomains are
shown in magenta
Fig. 6 Cleavage of human
fibrinogen by Plm (from
reference [48]). Schematic
representation of fibrinogen, the
fibrin polymer, the pattern of
cleavage by Plm, and the main
fragments generated. The main
Plm cleavage sites are indicated
by arrows. Cleavage of fibrin by
Plm leads to the main fragments
X (260 kDa), Y (160 kDa), D
(100 kDa), and E (60 kDa)
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Tissue-type plasminogen activator
Human tPA (P00750, EC 3.4.21.68; concentration in
plasma 5–10 lg l-1) is synthesized by various cell types
such as endothelial cells and keratinocytes and also in the
brain [63, 64]. It is a single-chain multidomain glycopro-
tein (about 7% CHO) of 70 kDa (527 amino acids)
containing one O-glycosylation site at Thr61 and three
N-glycosylation sites at Asn117, Asn184 (partial), and
Asn448 [65, 66] and belongs to the peptidase S1 family
[67]. The tPA gene (PLAT, 32.4 kb) is located on chro-
mosome 8p12 and is organized into 14 exons in the range
43–914 bp [68, 69]. The single-chain form (proenzyme)
itself exhibits a very high enzymatic activity compared
with the fully active two-chain form of tPA, which is a
unique property of the proenzyme form of serine proteases.
The single-chain form is converted to the completely
active, two-chain form held together by a single interchain
disulfide bridge (Cys264–Cys395) upon cleavage of the
Arg275–Ile276 peptide bond by Plm, kallikrein, or coagu-
lation factor Xa [70]. The A-chain (275 amino acids)
contains one FN1, one EGF-like, and two kringle domains
and the B-chain (252 amino acids) comprises the serine
protease part [71]. The second kringle in tPA carries an
active LBS as do the kringles in Pgn [72], but kringle 1 is
devoid of an active LBS. This seems to be due to the
replacement of the usual Trp residue by a Ser in the
hydrophobic cleft of the LBS in tPA kringle 1 [73].
The 3-D structure of the double module FN1?EGF-like
was determined by NMR spectroscopy (1TPG) and is
shown in Fig. 7a [74]. The FN1 domain (43 amino acids) is
characterized by two antiparallel b-sheets, a double stran-
ded sheet and a triple-stranded sheet (shown in red),
stabilized by two intrachain disulfide bridges arranged in
the pattern Cys1–Cys3, Cys2–Cys4. The first disulfide
bridge links the two b-sheets, the second disulfide bridge is
located within the triple-stranded b-sheet. The EGF-like
domain (39 amino acids) is characterized by two antipar-
allel, two-stranded b-sheets (shown in blue) interconnected
by a loop structure. The structure is stabilized by three
intrachain disulfide bridges arranged in the pattern
Cys1–Cys3, Cys2–Cys4, Cys5–Cys6. It appears that the
FN1?EGF-like double module, the two kringles, and the
serine protease domain are involved in the interaction of
tPA with fibrin [75, 76]. tPA binds with high affinity to
fibrin, resulting in an enhanced activation of Pgn by tPA.
Exposed C-terminal Lys and Arg residues in fibrin gener-
ated by proteolysis with Plm bind to the LBS in kringle 2 of
tPA [77]. The 3-D structure of the catalytic domain of
human tPA in complex with a low molecular weight
(LMW) inhibitor (dansyl-EGR-chloromethyl ketone) was
determined by X-ray diffraction (1RTF) and exhibits the
expected trypsin-like fold (Fig. 7b) [78]. The inhibitor is
covalently bound to His322 and Ser478 in the active site cleft
of tPA located at the interface of the two subdomains. Lys429
forms a salt bridge with Asp477 promoting an active con-
formation in single-chain tPA. The single-chain, proenzyme
form of tPA exhibits only a five to tenfold decreased activity
compared with fully active, two-chain tPA [79]. Both forms
seem to exhibit the same biological function.
Interactions of tPA with endothelial cells and smooth
muscle vascular cells lead to an increased activation of
Pgn. In the case of endothelial cells, the Ca2?/phospho-
lipid-binding protein annexin A2 (P07755) binds via its
exposed C-terminal Lys and Arg residues to the kringle 2
domain of tPA [80, 81].
The main physiological inhibitors of tPA are PAI-1 and
PAI-2, which are discussed in section Plasminogen acti-
vator inhibitor 1 and Plasminogen activator inhibitor 2,
respectively. An increased activity of tPA leads to hyper-
fibrinolysis (MIM 173370), an excessive bleeding disorder
Fig. 7 a 3-D structure of the double module of human tPA
comprising the fibronectin type I (FN1) domain and the epidermal
growth factor-like (EGF-like) domain determined by NMR spectros-
copy (1TPG, [74]). The disulfide bridges shown in yellow exhibit the
following patterns: in FN1 (red) Cys1–Cys3, Cys2–Cys4, and in EGF-
like (blue) Cys1–Cys3, Cys2–Cys4, Cys5–Cys6. b 3-D structure of the
catalytic domain of human tPA in complex with the LMW inhibitor
dansyl-EGR-chloromethyl ketone determined by X-ray diffraction
(1BDA, [78]). The inhibitor shown in red is covalently bound to
His322 and Ser478 in the active site cleft (magenta)
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[82]. There are several forms of tPA in therapeutic use,
among them alteplase (Activase, Genentech) and reteplase
(Retavase, Centocor, and Roche), which are used to initiate
fibrinolysis in the case of acute myocardial infarction,
acute ischaemic stroke, and pulmonary embolism.
Urokinase-type plasminogen activator
Human uPA (P00749, EC 3.4.21.73; concentration in
plasma 5–10 lg l-1) is synthesized in the lung and the
kidney, but also in keratinocytes and endothelial cells [83,
84]. It is a single-chain multidomain glycoprotein (about
2% CHO) of 55 kDa (411 amino acids) [85, 86] containing
one O-glycosylation site at Thr18 and one N-glycosylation
site at Asn302 and two phosphorylation sites at Ser138 and
Ser303 [87, 88]. The phosphorylation of Ser138/Ser303 seems
to modulate the urokinase receptor (uPAR) transducing
ability [88]. The uPA gene (PLAU, 6.4 kb) is located on
chromosome 10q24 and is organized into 11 exons [89].
Human uPA is converted to its active, two-chain high
molecular weight form held together by a single interchain
disulfide bridge (Cys148–Cys279) upon cleavage of the
Lys158 –Ile159 peptide bond by Plm, kallikrein, coagulation
factor XIIa, or cathepsin [90]. The A-chain (157 amino
acids) contains one EGF-like and one kringle domain and
the B-chain (253 amino acids) comprises the serine pro-
tease part. In addition to the high molecular weight form,
there is also a LMW form of uPA, the major form found in
urine. The LMW form of uPA is generated by Plm or by
uPA itself cleaving the Lys135–Lys136 peptide bond. Thus
LMW uPA is devoid of the EGF-like and kringle domains,
and the former A-chain consists only of a minichain (22
amino acids) linked to the catalytic domain by a single
interchain disulfide bridge [91].
The 3-D structure of the double domain EGF-
like?kringle determined by NMR spectroscopy (1URK) is
shown in Fig. 8a [92]. The EGF-like module exhibits the
same structural fold as the corresponding domain in tPA
(Fig. 7a) and the kringle domain resembles the kringles in
other kringle-containing proteins, e.g. human Pgn (Fig. 4).
The kringle structure in uPA is devoid of an active LBS
due to the replacement of essential residues in the cationic
(Lys?Tyr) and anionic (Asp?Arg) centres and two aro-
matic residues in the hydrophobic groove of the LBS.
Three consecutive Arg residues (Arg108–Arg110) and two
His residues (His85 and His87) at the opposite ends of the
kringle domain are involved in heparin binding [93, 94].
The EGF-like module mediates binding to its specific
cellular receptor uPAR [95, 96]. The 3-D structure of
human LMW uPA was determined by X-ray diffraction
(1GJA) and is shown in Fig. 8b [97]. The serine protease
part exhibits the expected trypsin-like fold with two sub-
domains each containing one antiparallel b-barrel and the
active site cleft with the catalytic triad is located at the
interface of the two subdomains. The minichain (in red) is
linked to the catalytic domain by a single interchain
disulfide bridge (in yellow).
The main physiological inhibitors of uPA are PAI-1 and
PAI-2, which are discussed in section Plasminogen acti-
vator inhibitor 1 and Plasminogen activator inhibitor 2,
respectively. The uPA system consisting of the serine
proteases Plm and uPA, the serpins A2PI, PAI-1, and
PAI-2, and uPAR seems to play an important role in cancer
metastasis [98]. uPA is available under the name Abbo-
kinase (Abbott) and is used clinically in the treatment of
thrombolytic disorders (pulmonary embolism).
Serine protease inhibitors (serpins) [99–102]
The regulation of proteolytic activity is a fundamental
process in all living organisms. Serine protease inhibitors
(serpins) are inhibitors (mass range 40–70 kDa) of serine
proteases and more than 1,500 serpin-like genes have been
identified so far in all three kingdoms of life as well as in
Fig. 8 a 3-D structure of the EGF-like (blue) and kringle (green)
double domain of human uPA determined by NMR spectroscopy
(1URK, [92]). The disulfide bridges are shown in yellow and are
arranged as in Fig. 7a (EGF-like) and Fig. 4 (kringle). b 3-D structure
of human LMW uPA determined by X-ray diffraction (1GJA, [96]).
The minichain (red) is linked to the catalytic domain by a single
interchain disulfide bridge (yellow)
Plasmin–antiplasmin system 791
viruses [101, 103, 104]. Serpins regulate very diverse
physiological processes such as coagulation and fibrinoly-
sis, complement activation, inflammation, angiogenesis,
apoptosis, neoplasia, and viral pathogenesis.
Inhibitory serpins are different from other inhibitors in
blood plasma in the sense that they are consumed in a one-
to-one reaction known as ‘suicide inhibition’. The standard
serpin structure is characterized by a conserved core
structure usually built of three b-sheets (A, B, and C in red,
green, and yellow, respectively), nine a-helices (hA–hI in
grey), and the reactive centre loop (RCL in blue) con-
taining the serine protease recognition site with the scissile
peptide bond (P1–P10). Serpins exist in different confor-
mational states, some of which have been characterized in
detail as can be seen in Fig. 9 [100]. The various confor-
mational states carry characteristic features:
1. The native state: the native state is usually character-
ized by three b-sheets A, B, and C, nine a-helices
hA–hI, and an RCL of approximately 20 amino acids
located on the surface of the molecule.
2. The latent, inserted state: in the latent state the RCL is
inserted into b-sheet A. This uncleaved, stressed state is
metastable and is often compared with a spring under
tension.
3. The cleaved state: in the cleaved state the stress is
released, the scissile peptide bond P1–P10 in the RCL
is cleaved, and the N- and C-terminal ends of the
cleaved peptide bond are now on either side of the
molecule, often as far apart as 70 A˚.
4. The serpin–serine protease complex: in the first step of
the inhibition reaction a noncovalent Michaelis-like
complex is formed between the serpin and the serine
protease characterized by an interaction between the
RCL of the serpin and the catalytic triad of the serine
protease.
5. Cleaved serpin with inactivated serine protease: upon
insertion of the RCL into b-sheet A the serine protease
is drawn from one side of the serpin to the opposite
side and the cleavage of the reactive peptide bond
releases the tension. The serpin is now covalently
linked to the side-chain of the serine residue in the
catalytic triad of the serine protease.
The inhibition of a serine protease by a serpin is a two-
stage process [105]:
1. The first step is a fast and reversible second-order
reaction leading to a noncovalent 1:1 Michaelis-like
complex of the serpin with the serine protease.
2. The second step is a slower and irreversible first-
order reaction with the insertion of the RCL into
b-sheet A and the subsequent cleavage of the
reactive peptide bond P1–P10 in the RCL, resulting
in the covalent attachment of the serpin to the side-
chain of the Ser residue in the catalytic triad of the
serine protease.
Plasmin inhibitors
The main physiological inhibitor of Plm is the serpin A2PI
which has unique N- and C-terminal extensions and as a
Fig. 9 Various conformational states of serpins [100]. a Native state
of human a1-antitrypsin (1QLP). b Latent, inserted state of human
antithrombin III (2ANT). c Cleaved state of human a1-antitrypsin
(7API). d Noncovalent, Michaelis-like complex of alaserpin (from
Manduca sexta) in complex with rat trypsin (1I99). e Cleaved serpin
with inactivated serine protease of human a1-antitrypsin with bovine
trypsin (1EZX)
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consequence also has special biological properties. In
addition, Plm activity is also regulated by the general
protease inhibitor a2M.
a2-Antiplasmin or a2-plasmin inhibitor [106, 107]
Human A2PI, also termed a2-plasmin inhibitor (P08697;
concentration in plasma: about 70 mg l-1), a member of
the serpin superfamily, is a single-chain plasma glycopro-
tein (14% CHO) of about 67 kDa primarily synthesized in
the liver [108, 109]. It contains four fully glycosylated
N-glycosylation sites (Asn87, Asn250, Asn270, Asn277) [110,
111], a single disulfide bridge (Cys31–Cys104), two Cys
residues (Cys64 and Cys113) of undefined state [112], and a
sulfated Tyr residue (Tyr445) of unknown function [113].
The A2PI gene (SERPINF2, about 16 kb) is located on
chromosome 17p13.3 and is organized into ten exons
[114]. In human plasma, two N-terminally different forms
are in circulation: (1) a form with 464 residues with Met as
N-terminus (Met-A2PI), and (2) a form with 452 residues
with Asn as N-terminus (Asn-A2PI) [115, 116]. Approxi-
mately 30% of mature A2PI circulates in human plasma in
a C-terminally truncated form lacking at least 26 amino
acids [117]. This truncated form inhibits Plm less rapidly
than mature A2PI [118, 119]. The RCL contains the scis-
sile peptide bond P1–P10 at Arg364–Met365 [120]. So far, no
3-D structure of human A2PI is available. However, the
3-D structure of a N-terminally truncated form of murine
A2PI (Q61247) sharing 71% sequence identity with human
A2PI was determined by X-ray diffraction (2R9Y) [121].
As expected, murine A2PI exhibits the typical fold of the
serpin core structure with three b-sheets and nine a-helices.
However, the 3-D structures of the unique N- and C-ter-
minal extensions of A2PI are still unsolved. In the
N-terminal segment of A2PI Gln2 forms an isopeptide bond
with Lys303 in the Aa chain of fibrin(ogen) catalysed by
activated coagulation factor XIIIa [122, 123]. The unique
C-terminal extension of A2PI (about 55 amino acids)
containing the plasmin(ogen) binding site reveals a
remarkable sequence identity between human and other
species in the range 58–70%. The C-terminal extension of
A2PI is characterized by four totally and two partially
conserved Lys residues, of which the C-terminal Lys452 is
most likely the main binding partner to the LBS in the Pgn
kringle domains and Lys436 seems to exhibit a cooperative
effect [32, 44]. In contrast, Wang et al. [33, 124] empha-
sized that Lys436 is the main binding partner and Lys452 has
no significant influence on the binding to the LBS in the
Pgn kringle domains.
A2PI is the main physiological inhibitor of Plm, the
main component of the fibrinolytic system, but A2PI also
inhibits chymotrypsin and trypsin. Kinetic data show a
two-step reaction for the rapid inhibition of Plm: a
reversible second order reaction (k1 about 3.8 ±
0.4 9 107 M-1s-1) followed by an irreversible first-order
reaction (k2 about 4.2 ± 0.4 9 10
6 M-1s-1) [31, 125–
128]. In the case of chymotrypsin the reactive bond in the
RCL is moved one position further down to the C-terminus
of A2PI, to Met365–Ser366, and the association constant
(Ka) for inhibiting bovine chymotrypsin is 6.7 9
105 M-1s-1 [129].
Defects in the SERPINF2 gene result in A2PI deficiency
(MIM 262850), an autosomal recessive disorder causing
severe haemorrhagic diathesis, an unusual susceptibility to
bleeding ([130, 131].
a2-Macroglobulin [132]
Human a2M (P01023; concentration in plasma about
1,200 mg l-1) is a member of the protease inhibitor I39
family. It is primarily synthesized in the liver [133]. The
a2M gene (A2M, about 48 kb) is located on chromosome
12p13.3-p12.3 and consists of 36 exons in the range
21–229 bp [134]. Mature a2M is a large single-chain plasma
glycoprotein (about 10% CHO) of 1,451 amino acids con-
taining eight N-glycosylation sites at Asn32, Asn47, Asn224,
Asn373, Asn387, Asn846, Asn968, and Asn1401 [135]. In
plasma, a2M is present as a tetramer (about 720 kDa)
composed of two noncovalently associated dimers oriented
in an antiparallel fashion, and the two monomers in the
dimers are held together covalently by two interchain
disulfide bridges (Cys255–Cys408, Cys408–Cys255) [136].
Gln670 and Gln671 are potential crosslinking sites, with the
side-chains of Lys residues in other proteins forming iso-
peptide bonds comparable to Gln2 in Asn-A2PI (see section
a2-Antiplasmin or a2-plasmin inhibitor). Like the structur-
ally related complement components C3 (P01024) and C4
(P0C0L4, P0C0L5), a2M contains a reactive isoglutamyl
cysteine thioester bond Cys949–Gly–Glu–Gln952. a2M con-
tains a ‘bait’ region of 39 amino acids (Pro667–Thr705) with
three short inhibitory sequence segments (Arg681–Glu686,
Arg696–Val700, Thr707–Phe712) [137].
a2M is a general inhibitor of all four types of proteases
and acts as a scavenger. Limited proteolysis in the ‘bait’
region of a2M at specific cleavage sites by the active
protease induces a large conformational change in a2M,
resulting in the trapping of the protease in a large central
cavity [135]. Concomitantly, the internal thioester bond is
cleaved, which mediates the covalent binding of a2M to the
protease. In the case of Plm, it appears that proteolysis and
conformational changes in a2M are limited to one of the
two subunits and the association constant Ka for Plm is
1.3 9 105 M-1s-1 [138].
a2M seems to be associated with Alzheimer disease
(MIM 103950) and a deletion in exon 18 seems to be the
cause of an increased risk of Alzheimer disease [139].
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Plasminogen activator inhibitors
There are two main physiological plasminogen activator
inhibitors, PAI-1 and PAI-2, which are more or less
directly involved in the inhibition process of the main
plasminogen activators, tPA and uPA. In addition, neuro-
serpin (predominantly expressed in the brain) mainly
inhibits tPA, uPA, and Plm, whereas glia-derived nexin has
a broader specificity, but also inhibits uPA and Plm.
Plasminogen activator inhibitor 1
Human PAI-1 (P05121; concentration in plasma about
20 lg l-1, variable) is a member of the serpin superfamily.
It is produced by a variety of cells such as endothelial cells,
smooth muscle cells, and liver cells [140]. PAI-1 is a single-
chain plasma glycoprotein (13% CHO) of 50 kDa (379
amino acids) containing three N-glycosylation sites at
Asn209, Asn265, and Asn329 (potential) [141]. The PAI-1
gene (SERPINE1, 12.2 kb) is located on chromosome
7q21.3-q22 and consists of nine exons [142]. The scissile
peptide bond P1–P10 is located at Arg346–Met347 [141, 143].
The 3-D structure of PAI-1 in complex with two inhibitory
RCL pentapeptides (Ac-TVASS-NH2) was determined by
X-ray diffraction (1A7C) and is shown in Fig. 10 [144]. The
two pentapeptides (in blue) bind between the space of
b-strands 3 and 5 in b-sheet A (in red). This prevents the
insertion of the RCL into b-sheet A and as a consequence
abolishes the inhibitory reaction with the target serine
protease. This form of PAI-1 exhibits the typical structural
features of cleaved serpins with the cleaved regions of the
RCL on either side of the molecule (red circles) and the
cleaved C-terminal region is shown in magenta.
PAI-1 primarily inhibits tPA and uPA with second-order
rate constants of 2.5–4 9 107 M-1s-1 for two-chain tPA and
1 9 107 M-1s-1 for uPA, thus regulating fibrinolysis by
limiting the Plm production. In addition, PAI-1 also inhibits
other serine proteases, but at much slower rates, e.g. thrombin
(1.1 9 103 M-1s-1), Plm (6.6 9 105 M-1s-1, bovine
PAI-1), trypsin (7 9 106 M-1s-1), and activated protein C
[145–148]. PAI-1 is bound to vitronectin (P04004) in plasma
and in the extracellular matrix [149]. Vitronectin and also
heparin enhance the inhibition rate constant of PAI-1 for
thrombin by a factor of up to 200-fold [150]. In the case of a
vascular injury, activated platelets can increase the low
plasma concentration of PAI-1 by a factor of 10 [151, 152].
Defects in the SERPINE1 gene are the cause of PAI-1
deficiency (MIM 173360), characterized by an abnormal
bleeding tendency [153]. High levels of PAI-1 seem to be
associated with myocardial infarction [154].
Plasminogen activator inhibitor 2 [155, 156]
Human PAI-2 (P05120; concentration in plasma\5 lg l-1,
only detectable during pregnancy [157]) is a member of the
serpin superfamily. It is produced by epithelial cells, mono-
cytes and macrophages, and keratinocytes [158–162]. Due to
the lack of a proper signal sequence (it contains an inefficient
internal signal sequence [163]) PAI-2 is not efficiently
secreted and therefore accumulates intracellularly as a non-
glycosylated 47-kDa protein [164]. A small portion of single-
chain PAI-2 is secreted via a facultative translocation path-
way [165] as a 60-kDa (415 amino acids) plasma
glycoprotein containing three potential N-glycosylation sites
at Asn75, Asn115, and Asn339, and one assigned disulfide
bridge (Cys5–Cys405) [156]. The PAI-2 gene (SERPINB2,
16.4 kb) is located on chromosome 18q21.2-q22 and contains
eight exons [166, 167]. The scissile peptide bond P1–P10 is
located at Arg380–Thr381 [168]. As Gln2 in A2PI, Gln83,
Gln84, and Gln86 located in the C–D interhelical domain in
PAI-2 (in other serpins corresponding to the C–D loop) can
form isopeptide bonds with Lys residues in the Aa chain of
fibrinogen, i.e. Lys148, Lys176, Lys183, Lys230, Lys413, and
Lys457 catalysed by coagulation factor XIIIa [169, 170]. The
3-D structure of a deletion mutant (deletion of loop Asn66–
Gln98) of PAI-2 was determined by X-ray diffraction (1BY7)
and is shown in Fig. 11 [171]. This deletion mutant represents
the stressed state of a serpin with a disordered structure of the
Fig. 10 3-D structure of human PAI-1 in complex with two
inhibitory RCL pentapeptides (Ac-TVASS-NH2) determined by
X-ray diffraction (1A7C, [144]). The two pentapeptides (blue) bind
between b-strands 3 and 5 in b-sheet A (red). The cleaved C-terminal
region is shown in magenta and the cleaved ends of the reactive
peptide bond are located on either side of the molecule (red circles)
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RCL (the reconstructed RCL is represented as dashed, blue
line). A buried cluster of polar amino acids beneath b-sheet A
(in red), the so-called shutter region (indicated by a blue-
shaded oval) stabilizes the stressed as well as the relaxed
forms of serpins. As expected, the insertion of the RCL into
b-sheet A is essential for the inhibition reaction.
PAI-2 is an efficient inhibitor of tPA and uPA with
second-order rate constants of 0.8–1.2 9 104 M-1s-1 for
two-chain tPA and 2.4–2.7 9 106 M-1s-1 for uPA [172].
PAI-2 is only detectable in plasma during pregnancy and
probably has a role in maintaining the placenta or in
embryonic development [157]. As mentioned above, only a
small portion of PAI-2 is secreted. Intracellular PAI-2
exhibits other functions than inhibition of uPA and tPA,
e.g. PAI-2 influences cell proliferation and cell differenti-
ation, inhibits apoptosis, and alters gene expression.
Little is known of precisely described diseases related to
PAI-2 defects (MIM 173390).
Neuroserpin [173–175]
Neuroserpin (Q99574; usually not detectable in plasma) is a
member of the serpin superfamily. It is predominantly
expressed in the brain [176, 177]. Neuroserpin is a single-
chain glycoprotein of 55 kDa (394 amino acids) containing
three potential N-glycosylation sites at Asn141, Asn305, and
Asn385 [178, 179]. The neuroserpin gene (SERPINI1,
89.8 kb) is located on chromosome 3q26.1 and consists of
nine exons [176, 177]. The scissile peptide bond P1–P10 is
located at Arg346–Met347 [176]. The 3-D structure of unc-
leaved, native neuroserpin was determined by X-ray
diffraction (3F5N, 3F02) and is shown in Fig. 12 [180].
It contains the expected elements of the core structure of
serpins: three b-sheets (shown in red, green, and yellow), nine
a-helices (in grey), and the exposed RCL (in blue).
tPA, uPA, and Plm have been identified as the main targets
of neuroserpin activity [176, 180]. The corresponding asso-
ciation constants Ka for recombinant neuroserpin (chicken)
are: (1) 1.5 ± 0.2 9 105 M-1s-1 (sc-tPA), (2) 4.7 ± 0.8 9
104 M-1s-1 (uPA), and (3) 1.1 ± 0.1 9 105 M-1s-1 (Plm)
[181].
Neuroserpin seems to be involved in the formation and
reorganization of synaptic connections and may be
involved in the protection of neurons from cell damage by
tPA. Defects in the SERPINI1 gene are the cause of
familial encephalopathy characterized by neuroserpin
inclusion bodies [177, 182].
Glia-derived nexin
Human glia-derived nexin (P07093) is a member of the
serpin superfamily. It is synthesized by fibroblasts, heart
Fig. 11 3-D structure of a deletion mutant of human PAI-2
determined by X-ray diffraction (1BY7, [171]). The reconstructed
RCL is shown as a dashed blue line and the shutter region located
beneath b-sheet A (red) is shown as a blue-shaded oval
Fig. 12 3-D structure of uncleaved, native human neuroserpin
determined by X-ray diffraction (3F5N, 3F02, [180]). Neuroserpin
contains the typical structural elements of uncleaved, native serpins:
three b-sheets (red, green, yellow), nine a-helices (grey), and the
exposed RCL (blue)
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muscle cells, and kidney epithelial cells, and also in the
brain [183]. Glia-derived nexin is a single-chain plasma
glycoprotein (about 6% CHO) of 43 kDa (379 amino acids)
containing two potential N-glycosylation sites at Asn99 and
Asn140 [184]. The scissile peptide bond P1–P10 is located at
Arg346–Ser347 [185]. The glia-derived nexin gene (SER-
PINE2) is located on chromosome 2q33-q35 containing
nine exons [186, 187].
Glia-derived nexin has a broad specificity but it primarily
inhibits trypsin, thrombin, uPA, and Plm. It seems to be the
most important physiological regulator of a-thrombin in
tissues [183]. The association constants Ka are: (1)
4.2 ± 0.4 9 106 M-1s-1 (trypsin), (2) 6.0 ± 1.3 9
105 M-1s-1 (thrombin), (3) 1.5 ± 0.1 9 105 M-1s-1
(uPA), and (4) 1.3 ± 0.1 9 105 M-1s-1 (Plm) [184, 185].
Diseases related to defects in the SERPINE2 gene are
not very well understood (MIM 177010). However, the
SERPINE2 gene seems to be associated with chronic
obstructive pulmonary disease [187].
Concluding remarks
The plasmin–antiplasmin system contains two main protein
families, namely multidomain serine proteases represented
by Pgn, tPA, and uPA, and serpins represented primarily by
A2PI as well as PAI-1 and PAI-2. The data provide evi-
dence that the noncatalytic domains in multidomain serine
proteases such as kringles, FN1, or EGF-like domains
mediate efficient binding to the target structures, facilitat-
ing an efficient cleavage reaction of the corresponding
serine protease which is usually strictly limited to the
intended site. Thus, the described multidomain serine
proteases in the plasmin–antiplasmin system are well-
adapted proteins which efficiently fulfil their tasks. The
data provided show that the plasmin–antiplasmin system as
a every complex system is tightly regulated by a series of
physiological inhibitors, in this case primarily by serpins
such as A2PI, PAI-1, and PAI-2. Also these inhibitors are
very well adapted to their regulatory task.
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